Queiroz, Natália Sousa FreitasTeixeira, Fábio VieiraFreire, Caio Cesar FurtadoMotta, Marina PamponetDe Vasconcellos, Marcela Almeida MenezesChebli, Liliana AndradeHossne, Rogerio Saad [UNESP]2021-06-252021-06-252021-01-01Arquivos de Gastroenterologia, v. 58, n. 1, p. 2-4, 2021.1678-42190004-2803http://hdl.handle.net/11449/208634Mass vaccination offers the best strategy to fight against COVID-19 pandemic, and SARS-CoV2 vaccines are being approved in several countries for emergency use. In Brazil, vaccine approval is expected in the next few days, however potential concerns exist regarding vaccine recommendations for specific populations, such as patients with inflammatory bowel disease (IBD). To address these questions, the Brazilian IBD Study Group (GEDIIB) provides this practical advice with key recommendations about the COVID-19 vaccines in IBD population.2-4engArtigo10.1590/s0004-2803.202100000-022-s2.0-85105083787